Hematologic Malignancy
Lymphoid Leukemia
CI-CAN-00001101Explore in graph →
Hematologic827 active trials20 approved drugs95 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001101Explore in graph →
Clinical trials
3,262 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (489)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03088709 | Haploidentical Stem Cell Transplantation Using Post-Transplant Cyclophosphamide | terminated | Phase 2 | 5 | Loyola UniversityOTHER | 1 | Jul 10, 2024 | clinicaltrials |
| NCT02742090 | Evaluate the Efficacy and Safety of TGR-1202 in Participants With Chronic Lymphocytic Leukemia Who Are Intolerant to Prior Therapy | terminated | Phase 2 | 51 | TG Therapeutics, Inc.INDUSTRY | 1 | Jul 3, 2024 | clinicaltrials |
| NCT03801525 |
| Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V)(ULTRA-V) |
| terminated |
| Phase 2 / Phase 3 |
| 277 |
| TG Therapeutics, Inc.INDUSTRY |
| 1 |
| Apr 19, 2024 |
| clinicaltrials |
| NCT03422679 | Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies | terminated | Phase 1 / Phase 2 | 79 | Cellestia Biotech AGINDUSTRY | 6 | Jan 16, 2024 | clinicaltrials |
| NCT04785547 | ALL SCTped 2012 FORUM Add-on Study Blina Post HSCT | terminated | Phase 2 | 3 | Prof. Christina PetersOTHER | 10 | Jan 16, 2024 | clinicaltrials |
| NCT03572634 | Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL | terminated | Phase 1 / Phase 2 | 3 | Sumitomo Pharma America, Inc.INDUSTRY | 1 | Nov 9, 2023 | clinicaltrials |
| NCT02763384 | BL-8040 and Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma | terminated | Phase 2 | 12 | Washington University School of MedicineOTHER | 1 | Oct 31, 2023 | clinicaltrials |
| NCT02065869 | Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell Transplant | terminated | Phase 1 / Phase 2 | 187 | Bellicum PharmaceuticalsINDUSTRY | 2 | Sep 29, 2023 | clinicaltrials |
| NCT03733249 | Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study | terminated | Phase 1 / Phase 2 | 187 | Bellicum PharmaceuticalsINDUSTRY | 1 | Sep 26, 2023 | clinicaltrials |
| NCT01044745 | Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer | terminated | Phase 2 | 20 | University of NebraskaOTHER | 1 | Sep 6, 2023 | clinicaltrials |
| NCT04016805 | Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or Venetoclax | terminated | Phase 2 | 41 | TG Therapeutics, Inc.INDUSTRY | 1 | Jul 24, 2023 | clinicaltrials |
| NCT01013961 | Rituximab and Alemtuzumab in Treating Older Patients With Progressive Chronic Lymphocytic Leukemia | terminated | Phase 2 | 31 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Jun 28, 2023 | clinicaltrials |
| NCT02656303 | A Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With Umbralisib for Participants Previously Enrolled in Protocol UTX-TGR-304 | terminated | Phase 2 | 116 | TG Therapeutics, Inc.INDUSTRY | 4 | Jun 22, 2023 | clinicaltrials |
| NCT02935543 | CART19 in Adult Patients With Minimal Residual Disease During Upfront Treatment for ALL | terminated | Phase 2 | 1 | University of PennsylvaniaOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT04149821 | Umbralisib Plus Ublituximab (U2) in Progressive CLL After Novel Therapy | terminated | Phase 2 | 1 | Weill Medical College of Cornell UniversityOTHER | 1 | Jun 15, 2023 | clinicaltrials |
| NCT02440685 | A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 51 | Asana BioSciencesINDUSTRY | 2 | Jun 7, 2023 | clinicaltrials |
| NCT03705507 | International Trial of Selumetinib in Combination With Dexamethasone for the Treatment of Acute Lymphoblastic Leukaemia(SeluDex) | terminated | Phase 1 / Phase 2 | 12 | University of BirminghamOTHER | 3 | May 11, 2023 | clinicaltrials |
| NCT00558961 | Dose Escalation Study of Gleevec and Chlorambucil in Previously Treated Chronic Lymphocytic Leukemia Patients(GL-CLB-001) | terminated | Phase 1 / Phase 2 | 13 | Jewish General HospitalOTHER | 1 | Mar 27, 2023 | clinicaltrials |
| NCT04225676 | Study of Efficacy and Safety of Reinfusion of Tisagenlecleucel in Pediatric and Young Adult Patients With Acute Lymphoblastic Leukemia (ALL) | terminated | Phase 2 | 5 | Novartis PharmaceuticalsINDUSTRY | 1 | Jan 30, 2023 | clinicaltrials |
| NCT01028716 | Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies | terminated | Phase 2 | 46 | Fred Hutchinson Cancer CenterOTHER | 1 | Jan 23, 2023 | clinicaltrials |
| NCT03518112 | Low-Intensity Chemotherapy and Blinatumomab in Treating Patients With Philadelphia Chromosome Negative Relapsed or Refractory Acute Lymphoblastic Leukemia | terminated | Phase 2 | 6 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 4, 2022 | clinicaltrials |
| NCT04504708 | Dose-Escalation and Dose-Expansion Study of ZX-101A in Patients With Relapsed/Resistant or Refractory Advanced Hematologic Malignancies | terminated | Phase 1 / Phase 2 | 6 | Hangzhou Zenshine Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Oct 21, 2022 | clinicaltrials |
| NCT02225275 | Lenalidomide and Obinutuzumab in Treating Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | terminated | Phase 2 | 9 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 28, 2022 | clinicaltrials |
| NCT01440179 | SAR3419 in Acute Lymphoblastic Leukemia(MYRALL) | terminated | Phase 2 | 100 | SanofiINDUSTRY | 2 | Sep 21, 2022 | clinicaltrials |
| NCT03379051 | Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHL | terminated | Phase 1 / Phase 2 | 78 | TG Therapeutics, Inc.INDUSTRY | 1 | Aug 22, 2022 | clinicaltrials |
| NCT03207256 | Extension Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 Trials | terminated | Phase 2 | 51 | TG Therapeutics, Inc.INDUSTRY | 1 | Jul 21, 2022 | clinicaltrials |
| NCT01241786 | Study Examining the Combination of Revlimid (Lenalidomide)and Vidaza (Azacitidine) for Relapsed/Refractory CLL and SLL(VZCLLPI0146) | terminated | Phase 2 | 5 | Hackensack Meridian HealthOTHER | 1 | Jul 20, 2022 | clinicaltrials |
| NCT00961142 | Haploidentical Stem Cell Transplantation With CD3/CD19 Depletion and Reduced Intensity Conditioning in Patients With Acute Leukemia(CD3/CD19 Haplo) | terminated | Phase 2 | 23 | University Hospital TuebingenOTHER | 1 | Jul 5, 2022 | clinicaltrials |
| NCT02043587 | Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma | terminated | Phase 2 | 31 | University of California, San DiegoOTHER | 1 | May 2, 2022 | clinicaltrials |
| NCT00968864 | T-cell Depleted Alternative Donor Transplantation | terminated | Phase 2 | 53 | Wake Forest University Health SciencesOTHER | 1 | Apr 22, 2022 | clinicaltrials |
| NCT04155840 | Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | terminated | Phase 2 | 1 | University of WashingtonOTHER | 1 | Apr 11, 2022 | clinicaltrials |
| NCT03668392 | Asparaginase Activity Monitoring (AAM) in Adult Patients With Acute Lymphoblastic Leukemia (ALL)(ALL2518) | terminated | Phase 2 | 7 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Mar 16, 2022 | clinicaltrials |
| NCT04209621 | Duvelisib for Ibrutinib-Resistant Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | terminated | Phase 2 | 3 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Mar 9, 2022 | clinicaltrials |
| NCT04044560 | Blinatumomab for MRD in Pre-B ALL Patients Following Stem Cell Transplant(OZM-097) | terminated | Phase 2 | 8 | University of British ColumbiaOTHER | 1 | Feb 21, 2022 | clinicaltrials |
| NCT00792831 | Phase II Study of Histone-deacetylase Inhibitor ITF2357 in Refractory/Relapsed Lymphocytic Leukemia | terminated | Phase 2 | 3 | ItalfarmacoINDUSTRY | 1 | Jan 27, 2022 | clinicaltrials |
| NCT03153514 | Obinutuzumab Containing Conditioning Regimen for Patients With Poor Risk CLL or Richter's Transformation Requiring Allogeneic Stem Cell Transplantation(CLLTX1) | terminated | Phase 2 | 3 | German CLL Study GroupOTHER | 1 | Jan 5, 2022 | clinicaltrials |
| NCT02795520 | Pharmacological Study of Intravenous OTS167 in Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Advanced Myelodysplastic Syndromes, Advanced Myeloproliferative Neoplastic Disorders, or Advanced Chronic Myelogenous Leukemia | terminated | Phase 1 / Phase 2 | 32 | OncoTherapy Science, Inc.INDUSTRY | 1 | Nov 24, 2021 | clinicaltrials |
| NCT01620216 | Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia | terminated | Phase 2 | 12 | OHSU Knight Cancer InstituteOTHER | 1 | Nov 4, 2021 | clinicaltrials |
| NCT01585688 | Phase I/II Study of hLL1-DOX in Relapsed NHL and CLL | terminated | Phase 1 / Phase 2 | 13 | Gilead SciencesINDUSTRY | 1 | Oct 8, 2021 | clinicaltrials |
| NCT03742323 | REALIB-LLA-2017: Idelalisib in Patients With Acute Lymphoblastic Leukemia | terminated | Phase 1 / Phase 2 | 6 | PETHEMA FoundationOTHER | 1 | Sep 5, 2021 | clinicaltrials |
| NCT01805037 | Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas | terminated | Phase 1 / Phase 2 | 20 | Northwestern UniversityOTHER | 1 | Sep 1, 2021 | clinicaltrials |
| NCT00967343 | Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor | terminated | Phase 2 / Phase 3 | 40 | Kiadis PharmaINDUSTRY | 7 | Jun 14, 2021 | clinicaltrials |
| NCT02341209 | Doxycycline for the Treatment of Cutaneous T-Cell Lymphoma(CTCL) | terminated | Phase 2 | 1 | Rochester General HospitalOTHER | 1 | Apr 27, 2021 | clinicaltrials |
| NCT03094611 | Inotuzumab Ozogamicin in Treating Patients With Relapsed or Refractory CD22 Positive Acute Lymphoblastic Leukemia | terminated | Phase 2 | 4 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 12, 2021 | clinicaltrials |
| NCT00439296 | ABT-751 With Chemotherapy for Relapsed Pediatric ALL | terminated | Phase 1 / Phase 2 | 9 | Therapeutic Advances in Childhood Leukemia ConsortiumOTHER | 1 | Mar 17, 2021 | clinicaltrials |
| NCT01799889 | Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies | terminated | Phase 2 | 326 | Gilead SciencesINDUSTRY | 2 | Nov 19, 2020 | clinicaltrials |
| NCT01483690 | A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL | terminated | Phase 1 / Phase 2 | 23 | Therapeutic Advances in Childhood Leukemia ConsortiumOTHER | 2 | Oct 27, 2020 | clinicaltrials |
| NCT03037645 | Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers | terminated | Phase 1 / Phase 2 | 39 | Sunesis PharmaceuticalsINDUSTRY | 1 | Oct 19, 2020 | clinicaltrials |
| NCT00981799 | Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL | terminated | Phase 1 / Phase 2 | 23 | Therapeutic Advances in Childhood Leukemia ConsortiumOTHER | 7 | Oct 1, 2020 | clinicaltrials |
Data updated 22 days agoSource updated Jul 10, 2024source: clinicaltrials